Warning: mysql_num_rows() expects parameter 1 to be resource, boolean given in /home/ejman/depo/functions_site.php on line 2446

Open Access and Peer-reviewed
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal News & Announcements

Original Research 
RMJ. 2010; 35(2): 165-167

Use of Injection Solcoseryl for the treatment of oligohydramnios

Khurshid Shabbir Raja, Huma Tasleem.

To assess the efficacy of drug hemodialysate (solcoseryl) on liquor volume in intrauterine growth restricted (IUGR) babies and their outcome in view of APGAR score and their health status.
Patients and Methods
In this study, a total of 70 patients with IUGR were included and it was carried out at Shifa International Hospital and Shifa Foundation Community Health Clinic Islamabad from January 2006 to December 2008. The patients were divided in two groups with 35 in each group. In group one, no infusion of solcoseryl was given, only left lateral position and plenty of fluids were advised (Conventional therapy). In group two, 10 mg of solcoseryl was given in 500 ml of normal saline at the rate of 125 ml/hour per day after 28 weeks of gestation (Interventional therapy). If the patient was hypertensive, 500 ml of Dextrose water was used instead of normal saline. Minimum one dose and maximum 28 doses were used. Both groups were compared with level of amniotic fluid index before and after the treatment.
Out of 70 patients, frequency of IUGR in group one it was 6.832.24, (t = -3.28, 95% CI, -2.89 -.704),
Solcoseryl is the drug of choice in pregnant women with IUGR, especially after twenty eight week of gestation.

Key words: Solcoseryl, oligohyramnios, IUGR.

Warning: mysql_num_rows() expects parameter 1 to be resource, boolean given in /home/ejman/depo/functions_site.php on line 909
No manuscript




Indexed in WHO Index Medicus IMEMR, Emromedex, Pakmedinet, ExtraMED and Scopus

  Approved by the Higher Education Commission of Pakistan and Pakistan Medical and Dental Council


This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.

The articles in Rawal Medical Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.